• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Akero Therapeutics Inc.

    2/28/25 4:05:47 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKRO alert in real time by email
    S-8 1 d830727ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 28, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    AKERO THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   81-5266573

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    601 Gateway Boulevard, Suite 350

    South San Francisco, CA

      94080
    (Address of Principal Executive Offices)   (Zip Code)

    Akero Therapeutics, Inc. 2019 Stock Option and Incentive Plan

    Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan

    (Full title of the plans)

    Andrew Cheng

    President and Chief Executive Officer

    601 Gateway Boulevard, Suite 350

    South San Francisco, CA 94080

    (Name and address of agent for service)

    (650) 487-6488

    (Telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    STATEMENT OF INCORPORATION BY REFERENCE

    This Registration Statement on Form S-8 is filed to register the offer and sale of (i) an additional 2,895,320 shares of the Registrant’s common stock, $0.0001 par value per share, to be issued under the Registrant’s 2019 Stock Option and Incentive Plan and (ii) an additional 410,803 shares of the Registrant’s common stock, $0.0001 par value per share, to be issued under the Registrant’s 2019 Employee Stock Purchase Plan, for which Registration Statements on Form S-8 relating to the same employee benefit plans are effective.

    Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 filed by the Registrant on June 20, 2019 (File No.  333-232234), March 16, 2020 (File No. 333-237220), March 18, 2021 (File No. 333-254454), March  2, 2022 (File No. 333-263194), March  17, 2023 (File No. 333-270662) and February  29, 2024 (File No. 333-277531) related to the Registrant’s 2019 Stock Option and Incentive Plan and 2019 Employee Stock Purchase Plan are incorporated by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier Registration Statements are presented herein.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits

    Refer to the Exhibit Index on the next page for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.


    EXHIBIT INDEX

     

    Exhibit No.

      

    Description of Exhibit

     4.1    Fourth Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as amended (File No. 001-38944)) as filed with the SEC on June 24, 2019.
     4.2    Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as amended (File No. 001-38944)) as filed with the SEC on March 12, 2021.
     4.3    Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-38944) filed on June 12, 2024).
     4.4    Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A, as amended (File No. 333-231747) as filed with the SEC on June 10, 2019).
     5.1*    Opinion of Goodwin Procter LLP.
    23.1*    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
    23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on signature page).
    99.1    2019 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-231747)) as filed with the SEC on June 10, 2019.
    99.2    2019 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-231747)) as filed with the SEC on June 10, 2019.
    107*    Filing Fee Table.

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on this 28th day of February, 2025.

     

    AKERO THERAPEUTICS, INC.
    By:  

    /s/ Andrew Cheng

     

    Name: Andrew Cheng

    Title: President, Chief Executive Officer and Director

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Andrew Cheng and William White as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.


    Name

      

    Title

     

    Date

    /s/ Andrew Cheng

    Andrew Cheng, M.D., Ph.D.

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      February 28, 2025

    /s/ William White

    William White, J.D.

      

    Executive Vice President, Chief Financial Officer and Head of Corporate Development

    (Principal Financial Officer and Principal Accounting Officer)

      February 28, 2025

    /s/ Judy Chou

    Judy Chou, Ph.D.

       Director   February 28, 2025

    /s/ Seth L. Harrison

    Seth L. Harrison, M.D.

       Director   February 28, 2025

    /s/ Jane P. Henderson

    Jane P. Henderson

       Director   February 28, 2025

    /s/ Tom Heyman

    Tom Heyman

       Director   February 28, 2025

    /s/ Mark Iwicki

    Mark Iwicki

       Director   February 28, 2025

    /s/ Graham Walmsley

    Graham Walmsley, M.D., Ph.D.

       Director   February 28, 2025

    /s/ Yuan Xu

    Yuan Xu, Ph.D.

       Director   February 28, 2025
    Get the next $AKRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKRO

    DatePrice TargetRatingAnalyst
    1/30/2025$35.00 → $63.00Neutral → Buy
    BofA Securities
    1/27/2025$50.00 → $72.00Buy
    H.C. Wainwright
    11/18/2024$65.00Buy
    Citigroup
    4/22/2024$30.00Neutral
    BofA Securities
    9/19/2023$69.00Overweight
    Cantor Fitzgerald
    8/28/2023$83.00Buy
    UBS
    1/27/2023$40.00 → $65.00Equal-Weight → Overweight
    Morgan Stanley
    9/14/2022$10.00 → $50.00In-line → Outperform
    Evercore ISI
    More analyst ratings